Aragen Life Sciences IPO: Rs 800 Crore Plan Filed with SEBI

Aragen Life Sciences has filed draft papers with Sebi for an Initial Public Offering targeting Rs 800 crore. The Contract Research, Development, and Manufacturing Organization (CRDMO) seeks to raise capital through a fresh issue and an Offer for Sale.

IPO Structure Details

• The IPO includes a fresh issue component.
• An Offer for Sale (OFS) of 2.73 crore equity shares is also part of the offering.
• Selling shareholders comprise promoters and investor Goldman Sachs Capital Holdings.

The funds from the fresh issue are specifically earmarked for several key operational needs. These allocations aim to bolster the company’s financial health and expand its infrastructure.

Fresh Issue Funding Allocation

• Repayment or pre-payment of borrowings.
• Capital expenditure for new equipment and machinery at Hyderabad facilities.
• Capital expenditure at Aragen Biologics Pvt Ltd’s Bengaluru facility.
• General corporate purposes.

Established in 2000, Aragen Life Sciences operates as an integrated CRDMO. It provides services to global innovator companies and emerging firms across the life sciences sector. Its offerings span contract discovery, pre-clinical research, and contract development and manufacturing for both small molecules and biologics.

Customer Reach and Workforce

By fiscal year 2026, Aragen served a substantial global client base. The company reported 4,362 employees as of March 31, 2026.

• 591 global customers served in fiscal year 2026.
• Key markets include the US, Europe, Japan, India, and other Asia-Pacific regions.
• Clientele ranges from major pharmaceutical companies to biotechnology firms, animal health, agrochemicals, and specialty chemicals.

Several financial institutions are managing the IPO process. These book-running lead managers are guiding the offering.

Book-Running Lead Managers

• Axis Capital
• Citigroup Global Markets India
• Goldman Sachs (India) Securities Pvt Ltd
• JM Financial